New Pure Play Novartis Vows To Up Its Game – With Help From In-House Challenger Ronny Gal
‘US First’ Policy To Boost Growth
Having finally confirmed the Sandoz spin-off, Novartis will become a 'pure play' pharma company and focus on picking bigger blockbuster winners from both internal and external pipelines. CEO Vas Narasimhan talked details at an investor day in Basel.
You may also be interested in...
A smooth handover hints at an amicable departure for Jay Bradner, but also gives CEO Vas Narasimhan the chance to refresh strategy with a new team.
The final Phase III readout for Ilaris (canakinumab) in NSCLC, this time in the adjuvant setting, missed the primary endpoint. One more lung cancer trial is under way, a Phase II neoadjuvant study.
First-in-class iptacopan could help Novartis expand into kidney disease, and take on Alexion’s blockbuster rare disease franchise.